Targeting G1–S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors

ABSTRACT: Cancer cell proliferation requires precise control of E2F1 activity; excess activity promotes apoptosis. We developed cell-permeable and bioavailable macrocycles that selectively kill small cell lung cancer (SCLC) cells with inherent high E2F1 activity by blocking RxL-mediated interactions of cyclin A and cyclin B with select substrates. This work uncovers gain-of-function mechanisms by which cyclin A/Bi induce apoptosis in cancers with high E2F activity, and suggests cyclin A/Bi as a therapeutic strategy for SCLC and other cancers driven by high E2F activity.

ORGANISM(S): Homo sapiens

PROVIDER: GSE291451 | GEO | 2025/05/29

REPOSITORIES: GEO